Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252753 · ClinicalTrials.gov registry record
Observational Study Protocol: LIVER-R
A clinical trial of Hepatobiliary Cancers, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 4,490
- Enrollment target
- 20
- Study locations
NCT06252753: Recruiting study of Hepatobiliary Cancers, sponsored by AstraZeneca.
NCT06252753 is a study of Hepatobiliary Cancers that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,490 participants. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252753, a study of Hepatobiliary Cancers, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 4,490 participants
- Enrollment target
- 20
- Study locations
Study Summary
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence).
Primary Outcome
rwOS will be calculated as the time from the index date to date of death, by any cause.
Conditions Studied
Interventions
- OTHER Durvalumab-based combination therapies in observational study setting
Study Locations (20)
California
- Research Site - Coronado
- Research Site - Los Angeles
- Research Site - Walnut Creek
Florida
- Research Site - Clermont
- Research Site - Gainesville
- Research Site - Tampa
Alabama
- Research Site - Birmingham
- Research Site - Mobile
Illinois
- Research Site - Evergreen Park
- Research Site - Hinsdale
Pennsylvania
- Research Site - Bethlehem
- Research Site - Philadelphia
Texas
- Research Site - Dallas
- Research Site - Temple
Arizona
- Research Site - Phoenix
Georgia
- Research Site - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,490 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2030-12-30 |
What NCT06252753 shows while recruiting
NCT06252753 is an observational study that tracks outcomes without assigning an intervention. Its 4,490 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Hepatobiliary Cancers appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab-based combination therapies in observational study setting is the first listed.
NCT06252753 names 20 study sites across 12 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06252753 about?
NCT06252753 is a clinical study titled "Observational Study Protocol: LIVER-R". Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diag...
What is the current status of trial NCT06252753?
This trial is currently recruiting. The enrollment target is 4,490 participants. The study started on 2023-03-16. Estimated completion is 2030-12-30.
What conditions does trial NCT06252753 study?
This clinical trial studies the following conditions: Hepatobiliary Cancers.
What interventions are being tested in trial NCT06252753?
The interventions under investigation include: Durvalumab-based combination therapies in observational study setting (OTHER).
Who is sponsoring clinical trial NCT06252753?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252753 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- NCT07207564 · 4,500 participants
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI